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Objective: Late saphenous vein graft failure after coronary artery bypass graft
surgery is initiated by medial thickening and neointima formation, both of which are
mediated by the proliferation of vascular smooth muscle cells. Because porcine vein
grafts contain high levels of endothelin 1 receptor subtypes and endothelin 1
promotes the proliferation of vascular smooth muscle cells, the effect of adminis-
tration of the endothelin 1A receptor antagonist BSF 302146 ([]-[S]-2-[4,6-
dimethyl-pyrimidin-2-yloxy]-3,3-diphenyl-butanoic acid) on porcine vein graft
thickening was investigated.
Methods: Saphenous vein–carotid artery interposition grafting was performed in 4
groups of large white pigs (30-35 kg, n  10 for each group). BSF 302146 was
administered orally (3, 10, and 30 mg · kg1 · d1) for 4 weeks to one group of pigs,
and placebo was administered to the other group (control animals). Pigs were then
anesthetized, and the grafts were removed and fixed at 100 mm Hg with 4%
paraformaldehyde. Histologic sections were prepared, and graft morphometry was
carried out by using computer-aided planimetry.
Results: In vein grafts from animals treated with BSF 302146 compared with grafts
from control animals (untreated), there were significant dose-dependent reductions
in the increase in medial thickness and neointimal thickness, an increase in luminal
area, and a decrease in proliferating cell nuclear antigen–positive cells in the
medial-intimal area.
Conclusions: The administration of BSF 302146 reduces graft thickening and
promotes positive remodeling through an endothelin 1A–mediated effect on vascular
smooth muscle cell replication. The administration of this endothelin 1A receptor
antagonist might therefore be therapeutically effective in preventing late vein graft
failure in patients undergoing coronary artery bypass grafting.
Vein graft thickening and superimposed atherogenesis is the maincause of late failure after coronary artery bypass graft (CABG)surgery with autologous saphenous vein.1-3 Vein graft thickeningis determined on the basis of increased medial thickening andneointima formation, both of which involve the proliferation andmigration of vascular smooth muscle cells (VSMCs).4 Superim-
posed on these rapid events is atherogenesis, which ultimately leads to graft
occlusion in as many as 50% of patients within 10 years.1-3 Apart from aggressive
lipid-lowering therapy,5 there is no effective therapeutic intervention for late vein
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graft failure,4 and as such, this constitutes a considerable
clinical problem that needs to be urgently resolved.
Of the many factors implicated in vein graft disease,
endothelin-1 (ET-1) promotes VSMC migration and prolif-
eration6 and restenosis after balloon injury.7-10 Furthermore,
there are high endothelin 1A (ETA) receptor densities in the
tunica media and neointima of porcine saphenous vein
grafts,11 suggesting a role for ET-1 in mediating vein graft
thickening. ETA receptor density was also found to be
greater in ungrafted saphenous vein compared with in the
carotid artery,11 suggesting that the saphenous vein might
be more susceptible to ET-1–driven VSMC replication and
migration than arterial conduits. ET-1 also plays a contrib-
utory role in atherogenesis,12 the ultimate cause of vein
graft failure.2,3
These observations pointed to the potential use of an ETA
receptor antagonist to reduce graft thickening after CABG.
The effect of oral administration of the ETA receptor antag-
onist BSF 3021461313 on vein graft thickening was studied
in a porcine model of saphenous vein–carotid artery inter-
position grafting to test this hypothesis.14,15
Materials and Methods
Surgical Procedure
Studies were performed with Landrace pigs weighing 30 to 35 kg,
which received humane care according to the Home Office Animal
Care regulations. All animals underwent saphenous vein into ca-
rotid artery interposition grafting.14 Anesthesia was induced with
ketamine (30 mg) and atropine (0.6 mg) administered intramuscu-
larly. After endotracheal intubation, anesthesia was maintained
with halothane and oxygen, and animals were allowed to ventilate
spontaneously throughout. Heparin sodium (1 mg/kg) was admin-
istered intravenously, and a single dose of 250 mg of benzyl
penicillin was administered intramuscularly before skin incision. A
longitudinal incision was made on the outer aspect of the hind
limb. Approximately 10 cm of the vein was then dissected free of
surrounding tissue by using a no-touch technique, and all side
branches were secured with a 6-0 Prolene ligature (Ethicon Inc).
The vein was removed from the animal, rinsed in iso-osmotic
sodium chloride solution (0.9 g/L) containing 2 IU/mL heparin and
50 g/mL glyceryl trinitrate, and stored in the same solution at
room temperature (23°C) until needed.
A longitudinal neck incision was made just medial to the
sternomastoid muscle, and the common carotid artery was care-
fully dissected from the internal jugular vein and vagus nerve
within the carotid sheath. A 3-cm segment of the common carotid
artery was isolated between vascular clamps and excised, beveling
the cut ends obliquely to 45°. The saphenous vein was cut to the
appropriate length, reversed, and similarly beveled, and an end-
to-end anastomosis of the vein to the common carotid artery was
carried out by using a continuous 7-0 Prolene suture. Animals were
extubated and, when in a satisfactory condition, returned to their
pens and fed a normal chow diet.
The specific ETA receptor antagonist BSF 302146 ([]-[S]-2-
[4,6-dimethyl-pyrimidin-2-yloxy]-3,3-diphenyl-butanoic acid,
Knoll AG) was then administered to the pigs (3, 10, and 30 mg/kg;
n  10 for each drug dose) daily for 28 days mixed with a portion
of mashed potato to ensure complete intake of the drug. The
control group (n  10) was fed placebo. After 1 month, pigs were
reanesthetized as above, grafts were removed (including 1-cm
segments of the proximal and distal carotid arteries), and the
pressure was fixed ex vivo at 100 mm Hg by using 6% parafor-
maldehyde buffered with phosphate-buffered saline and postfixed
in the same solution for 24 hours before being rinsed in phosphate-
buffered saline and processed for wax embedding, histology, and
planimetry.14,15
Histology and Immunocytochemistry
Histology and immunocytochemistry were carried out as previ-
ously described.14,15 For histology, sections were dewaxed, rehy-
drated, and stained with hematoxylin and eosin or Miller’s elastic
van Gieson stain. For immunocytochemistry, sections were dew-
axed, rehydrated, and treated with hydrogen peroxide in methanol
to remove endogenous peroxidase, and the following staining was
carried out. For VSMCs, sections were treated with horse serum
diluted 1:3 with Tris-buffered saline (TBS; pH 7.4), drained, and
incubated with smooth muscle actin clone 1A4 monoclonal (Dako)
at 1:1000 overnight at 4°C. After washing in TBS, the sections
were treated with biotinylated goat anti-mouse (Dako) at 1:400
and, after washing in TBS, treated with streptavidin biotin com-
plex/horseradish peroxidase (Dako) followed by 3,3'-diaminoben-
zidine. The nuclei were counterstained with diluted Harris hema-
toxylin, dehydrated, and mounted.
For proliferating cell nuclear antigen (PCNA), sections were
microwaved in citrate buffer, quenched in 1:3 horse serum in TBS,
and then incubated with PCNA antibody diluted 1:100 overnight at
4°C. Sections were washed and then treated with 1:400 biotinyl-
ated goat anti-mouse antibody, followed by streptavidin biotin
complex/horseradish peroxidase. Visualization was achieved with
3,3'-diaminobenzidine, and then after counterstaining with diluted
hematoxylin and eosin, sections were dehydrated and mounted.
PCNA was apparent as dark brown staining of nuclei, whereas
cytoplasmic nuclei were stained blue.
Morphometric Analysis
Vessel wall dimensions were measured by means of computer-
aided planimetry with an Olympus BH-2 microscope with a color
video camera head (JVC TK-870E) coupled to a Microscale
TM/TC image analysis system (Digithurst Ltd). The area enclosed
by the endothelium and the internal elastic lamina defined the
intima, and the area between the internal and external elastic
lamina defined the media. Luminal, intimal, and medial perimeters
and areas were computed by using the luminal boundary and the
internal and external elastic lamina as delimiters, and mean values
were then calculated for all sections from the same graft. Average
intimal, medial, and total vessel wall thickness was derived from
the area and perimeter data for 5 sections from each graft, assum-
ing that the sections consisted of circular profiles, which was a
valid assumption because the tissues were fixed at normal perfu-
sion pressures. The number of cells positive for PCNA, as well as
PCNA-negative cells in the intima and media together, were
counted in 4 luminal fields (at 40 magnification) for each section
(5 sections per graft), and the percentage was calculated.14,15
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Data Analysis and Statistics
Data were collated and analyzed with Microsoft Excel, and non-
parametric statistical analysis was carried out by using an Inter-
cooled Stata 8 statistics package (Stata Corp). Although data did
not appear to be skewed, the Bartlett test for equality of variance
(a necessary assumption for a 1-way analysis of variance) was
significant, indicating that nonparametric methods of analysis were
required. Thus values are expressed as medians and interquartile
ranges and graphically as whisker box plots. When the effects of
drug treatments on vein graft planimetry were compared with
those in placebo-fed control animals, the Kruskal-Wallis test, a
nonparametric version of analysis of variance, was applied. Mann-
Whitney tests were then applied to test the statistical significance
of each of the treated groups individually for each drug dose
compared with placebo-treated control animals. A Bonferroni ad-
justment was then used (0.05/3). A Kendall -b test was used as a
measure of correlation for ordinal categoric data, which takes into
account the testing of whether drug effects were dose dependent.
Results
All grafts were patent 4 weeks after implantation. There
were statistically significant increases in neointimal thick-
ness, medial thickness, and luminal areas in saphenous vein
grafts 4 weeks after implantation compared with ungrafted
saphenous veins (Figures 1 and 2). There was a dose-
dependent and statistically significant increase in luminal
area in response to BSF 302146 administration compared
with that seen in placebo-fed control animals (Figures 1 and
2). There was a dose-dependent and statistically significant
decrease in medial thickness in vein grafts from pigs treated
with BSF 302146 compared with that in vein grafts from
Figure 1. Planimeteric analysis of vein grafts from pigs to which BSF 302146 was administered orally once daily
for 1 month before explantation: A, luminal area (LA); B, neointimal thickness (NT); and C, medial thickness (MT).
Data are expressed as medians and interquartile ranges with P values (n  10). Asterisks denote statistical
significance when comparing ungrafted saphenous vein with vein grafts from placebo-treated pigs (Mann-Whitney
test with a Bonferroni adjustment). By using the Kendall -b test, significant dose-response relationships were
obtained for BSF 302146 versus luminal area (P < .001), neointimal thickness (P < .001), and medial thickness
(P < .001).
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placebo-treated animals (Figures 1 and 2). Neointimal
thickness in vein grafts from pigs treated with BSF 302146
was reduced compared with that in vein grafts from un-
treated animals, which again was statistically significant at
3 and 30 mg/kg but not at 10 mg/kg. However, without
applying a Bonferroni adjustment, the effect at 10 mg/kg
was statistically significant, and there was also a highly
significant dose-response relationship between BSF 302146
and the reduction in neointimal thickness (Figure 1). A
statistically significant lower percentage of PCNA-positive
(proliferating) cells was detected in the intimal-medial re-
gions of the grafts obtained from animals treated with BSF
302146 compared with placebo-fed control animals (Table
1 and Figure 3). At 3 and 10 mg/kg BSF 302146, there were
Figure 2. Effect of oral administration of the ETA antagonist (BSF 302146) on neointima formation. Elastin van
Gieson–stained serial transverse sections of a representative control vein graft (A and B) and grafts 4 weeks after
administration of 3 mg (C and D), 10 mg (E and F), and 30 mg (G and H) of ETA antagonist. Arrows and arrowheads
in panels A, C, E, and G indicate the internal and external elastic lamina, respectively. The scale bar in panel A
applies to panels C, E, and G and represents 100 m. The scale bar in panel B applies to panels D, F, and H and
represents 250 m. The asterisk indicates the lumen.
Figure 3. Representative photomicrographs of PCNA-positive staining (brown, examples arrowed) and PCNA-
negative staining (blue) in the intimal-medial regions of vein grafts 1 month after implantation from placebo-treated
pigs (A) and pigs to which 30 mg/kg BSF 302146 was administered (B). Scale bar  50 m.
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no statistically significant differences in cell density com-
pared with that seen in untreated control animals, but at 30
mg/kg, there was a slight but still statistically significant
reduction in cell density (Table 2).
Discussion
The present study demonstrates that the oral administration
of an ETA receptor antagonist, BSF 302146, promotes a
marked and dose-dependent inhibition of medial and intimal
thickening, increased luminal area, and decreased PCNA-
positive cells in porcine saphenous vein grafts. In the same
pig model, we previously found a pronounced expression of
ETA receptors in the neointima and the tunica media of
saphenous vein grafts 1 month after implantation.11 Because
ET-1 promotes the proliferation and migration of VSMCs,
two central processes in medial thickening and neointima
formation,6 it is concluded that the effect of the antagonist
is mediated through the inhibition of these processes. Other
studies have also demonstrated the inhibitory capacity of
ET-1 receptor antagonists on neointima formation after
balloon injury in other animal models and in an in vitro
organ culture model of the human saphenous vein.6-10,16
Mediation of the effects of BSF 302146 by ETB receptors is
unlikely because BSF 302146 has a 78-fold greater affinity
for ETA compared with ETB receptors,13 and ETB receptors
are associated principally with microvessels and nerves
rather then the neointima or medial regions of porcine vein
grafts.11
It has been suggested that the saphenous vein graft is
particularly vulnerable to pathologic attack by ET-1.6,17
First, the pig saphenous vein contains a greater density of
ETA receptors than the carotid artery.11 This would render
the saphenous vein intrinsically susceptible to ET-1–medi-
ated graft thickening in the present model. Certainly the
incidence of graft failure is far less when arteries (eg,
internal thoracic artery) are used in CABG compared with
saphenous vein.2,3 Furthermore, because immediately after
implantation saphenous vein grafts are subjected to pulsatile
pressure and high shear stress,17 which in turn elicit ET-1
expression in vascular tissues and cells,18-20 it is likely that
hemodynamic forces will contribute to high intragraft levels
of ET-1. Indeed, it has been demonstrated that there is a
marked endogenous upregulation of ET-1 expression in
porcine vein grafts 1 month after implantation.11 Platelet
and leukocyte adhesion is also an immediate consequence
of vein graft implantation.21 In turn, these cells release ET-1
itself,21,22 as well as releasing a number of factors, including
cytokines, that promote the release of ET-1 from vascular
cells.23 Thus coupled with the high levels of ETA receptors,
the locally high concentrations of ET-1 associated with vein
graft implantation not only render the graft susceptible to
ET-1–induced pathology but also explain the present em-
phatic effect of the ET-1 antagonist.
In the present study there was marked positive remodel-
ing in response to the administration of BSF 302146 in that
luminal area increased in a dose-dependent manner. One
possible explanation for this is that the ET-1 antagonist
might attenuate matrix protein formation and deposition, in
particular collagen and elastin. It has been demonstrated that
ET-1 is a potent stimulator of collagen synthesis (type I and
III) in vascular tissues and cells.12 The prevention of matrix
deposition might therefore render the graft more susceptible
to distension and therefore to increased luminal area. Al-
though there was no change in the density of VSMCs (an
index of matrix protein deposition14,15) after administration
of BSF 302146 at 3 and 10 mg/kg, but a decrease with 30
mg/kg, an earlier effect of the antagonist on extracellular
TABLE 1. Percentage of cells with PCNA-positive nuclei relative to PCNA-negative nuclei in the intimal-medial regions
of vein grafts from pigs treated with the ETA antagonist BSF 302146 compared with percentages in control animals
Placebo 3 mg/kg 10 mg/kg 30 mg/kg
19.1 (15.9-23.0) 12.45 (11.8-13.6),*
P  .0001
10.25 (8.0-13.15),*
P  .0001
8.7 (7.4-8.2),*
P  .0001
Data are expressed as medians (interquartile ranges; n  10).
*Statistical when comparing vein grafts from animals treated with antagonist with those from control animals (untreated; Mann-Whitney test with a
Bonferroni adjustment)
TABLE 2. Cell density (number of cells per square millimeter) in the intimal-medial region of vein grafts from pigs treated
with BSF 302146 compared with density in control animals
Placebo 3 mg/kg 10 mg/kg 30 mg/kg
7500 (7200-7580) 7300 (7050-7442),
NS
7568 (7320-7820),
NS
7090 (6900-7240),*
P  .0028
Data are expressed as medians (interquartile ranges; n  10). NS, Not significant.
*Statistical when comparing vein grafts from animals treated with antagonist with those from control animals (untreated; Mann-Whitney test with a
Bonferroni adjustment)
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matrix protein deposition cannot be discounted and warrants
further study. ET-1 also downregulates inducible nitric ox-
ide synthase,24 and nitric oxide has been shown to inhibit
neointima formation.25 Thus the antagonism of ET-1 might
augment nitric oxide formation, which might contribute to
the observed effects of BSF 302146.
The early administration of the ETA antagonist might
exert a further beneficial effect on vein graft patency in the
longer term through the inhibition of atherogenesis, which,
when superimposed on neointima formation, leads ulti-
mately to vein graft failure.2,3 Increased ET-1 content and
ETA receptor density has long been associated with athero-
genesis.12,13 In an animal model the ETA receptor antago-
nist BMS 182874 has been shown to reduce early athero-
sclerosis.26 Recent studies have demonstrated that nonspecific
ET-1 receptor antagonism prevents early proatherogenic
events in cultured human VSMCs27 and that ET-1 promotes
the adhesion of monocytes to the endothelium.28
In conclusion, the potent inhibitory effect of BSF 302146
on porcine vein graft thickening helps confirm that that
ET-1 and ETA receptor subtypes are involved in medial
thickening and neointima formation in saphenous vein
grafts. It is also concluded that the effects of BSF 302146 on
vein graft morphology are mediated principally through the
inhibition of VSMC proliferation and migration. The ad-
ministration of this ETA antagonist might therefore prove
effective in preventing late vein graft failure in humans and
clinical trials would seem to be warranted.
We thank Dr Rosemary Greenwood, Resident Statistician,
Bristol Royal Infirmary.
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